: Investigating approaches where patients only take the drug for a set period, especially if they achieve a complete response, to avoid unnecessary long-term exposure and side effects. If you'd like, I can:
Explain the specific (toxicities) that led to these discontinuations. Compare these results to more recent ibrutinib studies .
: For those who stopped the medication, the median time until they did so was only 7 months . (616 KB)
The researchers analyzed a large group of 616 patients with who were treated with ibrutinib. The goal was to see if the high success rates found in clinical trials were mirrored in everyday medical practice across various hospitals. Key Findings and Statistics
: A major finding was that 41% of patients stopped taking ibrutinib within a median of 17 months. : Investigating approaches where patients only take the
: Finding ways to help patients manage side effects so they can stay on the therapy longer.
Toxicities and outcomes of 616 ibrutinib-treated patients in ... - PMC : For those who stopped the medication, the
: Despite the high rate of stopping, the overall survival and progression-free survival (estimated at 35 months) remained excellent. Real-World vs. Clinical Trials